

SKYEPHARMA PLC  
Form 6-K  
January 16, 2007

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January, 2007

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

FOR IMMEDIATE RELEASE

16 JANUARY 2007

**SkyePharma PLC**

**CIRCULAR POSTED TODAY TO SHAREHOLDERS**

London, England, 16 January, 2007 - SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) announces that, further to its announcement on 9 January 2007, a Circular, which details the proposed disposal of its Injectable Business and the proposed placing with certain institutional investors, will today be posted to shareholders of the Company.

The Circular includes a notice convening an Extraordinary General Meeting to be held on 8 February 2007 at 10am at Stringer Saul LLP, First Floor, 17 Hanover Square, London W1S 1HU at which resolutions will be proposed, inter alia, to approve the disposal and the issue of shares under the placing.

The Circular will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

**EXPECTED TIMETABLE OF KEY EVENTS**

Posting of Circular to Shareholders	16 January 2007
Latest time and date for receipt of Forms of Proxy	10am on 6 February 2007
Extraordinary General Meeting	10 am on 8 February 2007
Expected date of completion of the Disposal	9 February 2007
Expected date of Placing Shares being admitted	12 February 2007

**For further information please contact:**

**SkyePharma PLC**

Frank Condella, Chief Executive Officer  
Ken Cunningham, Chief Operating Officer  
Peter Grant, Finance Director

**+44 207 491 1777**

**Buchanan Communications**

Tim Anderson / Mark Court / Rebecca Skye Dietrich

**+44 207 466 5000**

**Trout Group (US)**

Seth Lewis

**+(1) 617-583-1308**

**Notes for editors**

**About SkyePharma**

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit [www.skyepharma.com](http://www.skyepharma.com).

*These materials are not an offer for sale of securities in the United States. The securities in the placing have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and the securities may not be*

Edgar Filing: SKYEPHARMA PLC - Form 6-K

*sold in the United States absent registration or an exemption from registration under the Securities Act. The Company does not intend to register any portion of such offering in the United States or to conduct a public offering of the ordinary shares in the United States.*

*The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ John Murphy

Name: John Murphy  
Title: Company Secretary

Date: January 16, 2007